The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Gene therapy rescues cone function in congenital achromatopsia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a recent study using gene therapy in a canine model of a CNGB3 defect showed rescue of cone photoreceptor function (Komáromy, Alexander, SRowlan, Garcia, Chiodo, Kaya, Tanaka, Acland, Hauswirth & Aguirre, 2010).”
From The genetics of normal and defective color vision (2011) · cites this paper as Komáromy et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationRosenfeld, P. J., Cowley, G. S., McGee, T. L., Sandberg, M. A., Berson, E. L., & Dryja, T. P. (1992) · Nature Genetics · doi:10.1038/ng0692-209 · Cited by 422
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224
Self-citation
Research works printed but not linked: 74
- Acland, 2005, Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness, Mol. Ther., 12, 1072, 10.1016/j.ymthe.2005.08.008 · DOI
- Pang, 2006, Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis, Mol. Ther., 13, 565, 10.1016/j.ymthe.2005.09.001 · DOI
- Hauswirth, 2008, Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial, Hum. Gene Ther., 19, 979, 10.1089/hum.2008.107 · DOI · Paper page
- Cideciyan, 2008, Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics, Proc. Natl Acad. Sci. USA, 105, 15112, 10.1073/pnas.0807027105 · DOI
- Cideciyan, 2009, Vision 1 year after gene therapy for Leber's congenital amaurosis, N. Engl. J. Med., 361, 725, 10.1056/NEJMc0903652 · DOI
- Cideciyan, 2009, Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year, Hum. Gene Ther., 20, 999, 10.1089/hum.2009.086 · DOI · Paper page
- Maguire, 2009, Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial, Lancet, 374, 1597, 10.1016/S0140-6736(09)61836-5 · DOI · Paper page
- Simonelli, 2010, Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration, Mol. Ther., 18, 643, 10.1038/mt.2009.277 · DOI
- Sharpe, 1990, Total colour blindness: an introduction, 253
- Michaelides, 2004, The cone dysfunction syndromes, Br. J. Ophthalmol., 88, 291, 10.1136/bjo.2003.027102 · DOI
- Michaelides, 2006, Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis, Surv. Ophthalmol., 51, 232, 10.1016/j.survophthal.2006.02.007 · DOI
- Simunovic, 1998, The cone dystrophies, Eye (Lond), 12, 553, 10.1038/eye.1998.145 · DOI
- Curcio, 1990, Human photoreceptor topography, J. Comp. Neurol., 292, 497, 10.1002/cne.902920402 · DOI
- Kohl, 2002, Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia, Am. J. Hum. Genet., 71, 422, 10.1086/341835 · DOI
- Aligianis, 2002, Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2), J. Med. Genet., 39, 656, 10.1136/jmg.39.9.656 · DOI · Paper page
- Rosenberg, 2004, Variant phenotypes of incomplete achromatopsia in two cousins with GNAT2 gene mutations, Invest. Ophthalmol. Vis. Sci., 45, 4256, 10.1167/iovs.04-0317 · DOI
- Chang, 2009, A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene, Proc. Natl Acad. Sci. USA, 106, 19581, 10.1073/pnas.0907720106 · DOI
- Thiadens, 2009, Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders, Am. J. Hum. Genet., 85, 240, 10.1016/j.ajhg.2009.06.016 · DOI
- Wissinger, 2001, CNGA3 mutations in hereditary cone photoreceptor disorders, Am. J. Hum. Genet., 69, 722, 10.1086/323613 · DOI
- Kohl, 1998, Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel, Nat. Genet., 19, 257, 10.1038/935 · DOI
- Wissinger, 1998, Human rod monochromacy: linkage analysis and mapping of a cone photoreceptor expressed candidate gene on chromosome 2q11, Genomics, 51, 325, 10.1006/geno.1998.5390 · DOI
- Sundin, 2000, Genetic basis of total colourblindness among the Pingelapese islanders, Nat. Genet., 25, 289, 10.1038/77162 · DOI
- Winick, 1999, Homozygosity mapping of the achromatopsia locus in the Pingelapese, Am. J. Hum. Genet., 64, 1679, 10.1086/302423 · DOI
- Milunsky, 1999, A locus for autosomal recessive achromatopsia on human chromosome 8q, Clin. Genet., 56, 82, 10.1034/j.1399-0004.1999.560112.x · DOI
- Kohl, 2000, Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21, Hum. Mol. Genet., 9, 2107, 10.1093/hmg/9.14.2107 · DOI
- Kohl, 2005, CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia, Eur. J. Hum. Genet., 13, 302, 10.1038/sj.ejhg.5201269 · DOI
- Varsanyi, 2005, Clinical and genetic features of Hungarian achromatopsia patients, Mol. Vis., 11, 996
- Wiszniewski, 2007, Achromatopsia: the CNGB3 p.T383fsX mutation results from a founder effect and is responsible for the visual phenotype in the original report of uniparental disomy 14, Hum. Genet., 121, 433, 10.1007/s00439-006-0314-y · DOI
- Thiadens, 2009, Genetic etiology and clinical consequences of complete and incomplete achromatopsia, Ophthalmology, 116, 1984, 10.1016/j.ophtha.2009.03.053 · DOI
- Ahuja, 2008, CNGA3 mutations in two United Arab Emirates families with achromatopsia, Mol. Vis., 14, 1293
- Sidjanin, 2002, Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3, Hum. Mol. Genet., 11, 1823, 10.1093/hmg/11.16.1823 · DOI
- Aguirre, 1975, The electroretinogram in dogs with inherited cone degeneration, Invest. Ophthalmol., 14, 840
- Aguirre, 1974, Pathology of hemeralopia in the Alaskan malamute dog, Invest. Ophthalmol., 13, 231
- Rubin, 1971, Hemeralopia in Alaskan malamute pups, J. Am. Vet. Med. Assoc., 158, 1699
- Rubin, 1971, Clinical features of hemeralopia in the adult Alaskan malamute, J. Am. Vet. Med. Assoc., 158, 1696
- Jacobs, 1993, Photopigments of dogs and foxes and their implications for canid vision, Vis. Neurosci., 10, 173, 10.1017/S0952523800003291 · DOI
- Neitz, 1989, Color vision in the dog, Vis. Neurosci., 3, 119, 10.1017/S0952523800004430 · DOI
- Mowat, 2008, Topographical characterization of cone photoreceptors and the area centralis of the canine retina, Mol. Vis., 14, 2518
- Garcia, 2010, Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs, Am. J. Vet. Res., 71, 97, 10.2460/ajvr.71.1.97 · DOI
- Komáromy, 2008, Targeting gene expression to cones with human cone opsin promoters in recombinant AAV, Gene Ther., 15, 1049, 10.1038/gt.2008.32 · DOI
- Gropp, 1996, Selective absence of cone outer segment beta 3-transducin immunoreactivity in hereditary cone degeneration (cd), Exp. Eye Res., 63, 285, 10.1006/exer.1996.0117 · DOI
- Akhmedov, 1998, Canine cone transducin-gamma gene and cone degeneration in the cd dog, Invest. Ophthalmol. Vis. Sci., 39, 1775
- Le Meur, 2005, Postsurgical assessment and long-term safety of recombinant adeno-associated virus-mediated gene transfer into the retinas of dogs and primates, Arch. Ophthalmol., 123, 500, 10.1001/archopht.123.4.500 · DOI
- Weber, 2003, Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery, Mol. Ther., 7, 774, 10.1016/S1525-0016(03)00098-4 · DOI · Paper page
- Glushakova, 2006, Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors, Invest. Ophthalmol. Vis. Sci., 47, 3505, 10.1167/iovs.05-1670 · DOI
- Wang, 1992, A locus control region adjacent to the human red and green visual pigment genes, Neuron, 9, 429, 10.1016/0896-6273(92)90181-C · DOI · Paper page
- Khani, 2007, AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter, Invest. Ophthalmol. Vis. Sci., 48, 3954, 10.1167/iovs.07-0257 · DOI
- Mauck, 2008, Longitudinal evaluation of expression of virally delivered transgenes in gerbil cone photoreceptors, Vis. Neurosci., 25, 273, 10.1017/S0952523808080577 · DOI
- Curcio, 1991, Distribution and morphology of human cone photoreceptors stained with anti-blue opsin, J. Comp. Neurol., 312, 610, 10.1002/cne.903120411 · DOI
- Roorda, 2001, Packing arrangement of the three cone classes in primate retina, Vision Res., 41, 1291, 10.1016/S0042-6989(01)00043-8 · DOI
- Peng, 2004, Subunit configuration of heteromeric cone cyclic nucleotide-gated channels, Neuron, 42, 401, 10.1016/S0896-6273(04)00225-9 · DOI
- Aguirre, 2007, Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation, PLoS Med., 4, e230, 10.1371/journal.pmed.0040230 · DOI
- Bonigk, 1993, Rod and cone photoreceptor cells express distinct genes for cGMP-gated channels, Neuron, 10, 865, 10.1016/0896-6273(93)90202-3 · DOI
- Gerstner, 2000, Molecular cloning and functional characterization of a new modulatory cyclic nucleotide-gated channel subunit from mouse retina, J. Neurosci., 20, 1324, 10.1523/JNEUROSCI.20-04-01324.2000 · DOI
- Alexander, 2007, Restoration of cone vision in a mouse model of achromatopsia, Nat. Med., 13, 685, 10.1038/nm1596 · DOI
- Michalakis, 2005, Impaired opsin targeting and cone photoreceptor migration in the retina of mice lacking the cyclic nucleotide-gated channel CNGA3, Invest. Ophthalmol. Vis. Sci., 46, 1516, 10.1167/iovs.04-1503 · DOI
- Ding, 2009, Impaired cone function and cone degeneration resulting from CNGB3 deficiency: down-regulation of CNGA3 biosynthesis as a potential mechanism, Hum. Mol. Genet., 18, 4770, 10.1093/hmg/ddp440 · DOI
- Jacobs, 2007, Emergence of novel color vision in mice engineered to express a human cone photopigment, Science, 315, 1723, 10.1126/science.1138838 · DOI · Paper page
- Mancuso, 2009, Gene therapy for red-green colour blindness in adult primates, Nature, 461, 784, 10.1038/nature08401 · DOI · Paper page
- Baseler, 2002, Reorganization of human cortical maps caused by inherited photoreceptor abnormalities, Nat. Neurosci., 5, 364, 10.1038/nn817 · DOI
- Estevez, 1982, The ‘silent substitution’ method in visual research, Vision Res., 22, 681, 10.1016/0042-6989(82)90104-3 · DOI
- Mears, 2000, Remapping of the RP15 locus for X-linked cone-rod degeneration to Xp11.4-p21.1, and identification of a de novo insertion in the RPGR exon ORF15, Am. J. Hum. Genet., 67, 1000, 10.1086/303091 · DOI
- Fishman, 2003, ABCA4 gene sequence variations in patients with autosomal recessive cone-rod dystrophy, Arch. Ophthalmol., 121, 851, 10.1001/archopht.121.6.851 · DOI
- Curcio, 1996, Photoreceptor loss in age-related macular degeneration, Invest. Ophthalmol. Vis. Sci., 37, 1236
- Phipps, 2003, Loss of cone function in age-related maculopathy, Invest. Ophthalmol. Vis. Sci., 44, 2277, 10.1167/iovs.02-0769 · DOI
- McLaughlin, 1993, Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa, Nat. Genet., 4, 130, 10.1038/ng0693-130 · DOI
- Kajiwara, 1994, Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci, Science, 264, 1604, 10.1126/science.8202715 · DOI
- Zolotukhin, 2005, Production of recombinant adeno-associated virus vectors, Hum. Gene Ther., 16, 551, 10.1089/hum.2005.16.551 · DOI
- Zolotukhin, 2002, Production and purification of serotype 1, 2 and 5 recombinant adeno-associated viral vectors, Methods, 28, 158, 10.1016/S1046-2023(02)00220-7 · DOI
- Komáromy, 2006, Application of a new subretinal injection device in the dog, Cell Transplant., 15, 511, 10.3727/000000006783981701 · DOI
- Acland, 1987, Retinal degenerations in the dog: IV. Early retinal degeneration (erd) in Norwegian elkhounds, Exp. Eye Res., 44, 491, 10.1016/S0014-4835(87)80160-4 · DOI
- Acland, 1999, A novel retinal degeneration locus identified by linkage and comparative mapping of canine early retinal degeneration, Genomics, 59, 134, 10.1006/geno.1999.5842 · DOI
- Beltran, 2006, A frameshift mutation in RPGR exon ORF15 causes photoreceptor degeneration and inner retina remodeling in a model of X-linked retinitis pigmentosa, Invest. Ophthalmol. Vis. Sci., 47, 1669, 10.1167/iovs.05-0845 · DOI
- Patel, 2005, Transmembrane S1 mutations in CNGA3 from achromatopsia 2 patients cause loss of function and impaired cellular trafficking of the cone CNG channel, Invest. Ophthalmol. Vis. Sci., 46, 2282, 10.1167/iovs.05-0179 · DOI
Cited by
Sorted by citations
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
The genetics of normal and defective color vision
Neitz, J., & Neitz, M. (2011) · Vision Research · doi:10.1016/j.visres.2010.12.002 · Cited by 377
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Self-citationBeltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260
Self-citationLeber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
Self-citationNovel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Noninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124
Banin, E., Gootwine, E., Obolensky, A., Ezra-Elia, R., Ejzenberg, A., Zelinger, L., Honig, H., Rosov, A., Yamin, E., Sharon, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.114 · Cited by 113
Self-citationBoye, S. E., Alexander, J. J., Boye, S. L., Witherspoon, C. D., Sandefer, K. J., Conlon, T. J., Erger, K., Sun, J., Ryals, R., Chiodo, V. A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.125 · Cited by 117
Self-citationMowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Self-citationAAV9 targets cone photoreceptors in the nonhuman primate retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053463 · Cited by 97
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Advances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Long-term Structural Outcomes of Late-stage RPE65 Gene Therapy
Gardiner, K. L., Cideciyan, A. V., Swider, M., Dufour, V. L., Sumaroka, A., Komáromy, A. M., Hauswirth, W. W., Iwabe, S., Jacobson, S. G., Beltran, W. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.013 · Cited by 67
Self-citationGene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Ye, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64
Self-citationHohman, T. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_91 · Cited by 56
Michaelides, M., Hirji, N., Wong, S. C., Besirli, C. G., Zaman, S., Kumaran, N., Georgiadis, A., Smith, A. J., Ripamonti, C., Gottlob, I., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.05.009 · Cited by 54
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
Gootwine, E., Ofri, R., Banin, E., Obolensky, A., Averbukh, E., Ezra-Elia, R., Ross, M., Honig, H., Rosov, A., Yamin, E., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.028 · Cited by 36
Ofri, R., Averbukh, E., Ezra-Elia, R., Ross, M., Honig, H., Obolensky, A., Rosov, A., Hauswirth, W. W., Gootwine, E., & Banin, E. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.076 · Cited by 31
Self-citationOcular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Ross, M., Obolensky, A., Averbukh, E., Desrosiers, M., Ezra-Elia, R., Honig, H., Yamin, E., Rosov, A., Dvir, H., Gootwine, E., et al. (2022) · Gene Therapy · doi:10.1038/s41434-021-00306-1 · Cited by 13
Brydon, E. M., Bronstein, R., Buskin, A., Lako, M., Pierce, E. A., & Fernandez-Godino, R. (2019) · doi:10.1101/729160 · Cited by 56
Metadata
- Authors
- Komáromy, A. M., Alexander, J. J., Rowlan, J. S., Garcia, M. M., Chiodo, V. A., Kaya, A., Tanaka, J. C., Acland, G. M., Hauswirth, W. W., & Aguirre, G. D.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-08
- Volume
- 19
- Issue
- 13
- Pages
- 2581-2593
- ISSN
- 1460-2083
- 0964-6906
- Cited by
- 217
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review